<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190813</url>
  </required_header>
  <id_info>
    <org_study_id>ATS 17</org_study_id>
    <secondary_id>2U10EY011751</secondary_id>
    <nct_id>NCT01190813</nct_id>
  </id_info>
  <brief_title>Levodopa for the Treatment of Residual Amblyopia</brief_title>
  <acronym>ATS17</acronym>
  <official_title>A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of oral levodopa and
      patching versus oral placebo and patching as treatment for residual amblyopia in children 7
      to &lt;13 years old with visual acuity of 20/50 to 20/400 in the amblyopic eye.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amblyopia is the most common cause of monocular visual impairment in both children and young
      and middle-aged adults. Both patching and atropine are accepted treatment modalities for the
      management of moderate amblyopia in children. Despite best efforts with conventional
      amblyopia treatment, many older children and teenagers with amblyopia fail to achieve normal
      visual acuity in the amblyopic eye. In a previous PEDIG study where children 7 to 12 years
      old were treated with atropine and patching, only 36% of the children with moderate amblyopia
      and only 23% of the children with severe amblyopia achieved 20/40 or better acuity.

      Many clinicians have recognized that conventional therapies with patching and atropine have
      not been universally successful and have sought alternatives. PEDIG has discussed for several
      years the problem of residual amblyopia and how the remaining visual acuity deficit could be
      reduced. A number of research groups have evaluated the short term use of oral
      levodopa-carbidopa as an adjunct to patching therapy for older children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Amblyopic Eye Visual Acuity Change From Baseline</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Amblyopic Eye Visual Acuity at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopia Resolutionat 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopia Resolution at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopia Resolution at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopia Resolution at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amblyopia Resolution at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>A treatment group comparison of the mean amblyopic eye visual acuity at 4 weeks after enrollment, adjusted for baseline acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>A treatment group comparison of the mean amblyopic eye visual acuity at 10 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>A treatment group comparison of the mean amblyopic eye visual acuity at 16 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>A treatment group comparison of the mean amblyopic eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Fellow Eye Visual Acuity at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 18 weeks after enrollment, adjusted for baseline acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fellow Eye Visual Acuity at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at Enrollment</measure>
    <time_frame>At enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Child Symptom Survey Score at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at Enrollment</measure>
    <time_frame>At enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at 4 Weeks</measure>
    <time_frame>4 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at 16 Weeks</measure>
    <time_frame>16 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at 18 Weeks</measure>
    <time_frame>18 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Parent Symptom Survey Score at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systemic Adverse Events</measure>
    <time_frame>Enrollment through 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Fellow Eye Visual Acuity at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fellow Eye Visual Acuity at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</measure>
    <time_frame>26 weeks after enrollment</time_frame>
    <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>Levodopa/Carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/Carbidopa</intervention_name>
    <description>Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid</description>
    <arm_group_label>Levodopa/Carbidopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo tid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patching</intervention_name>
    <description>Two hours of daily patching</description>
    <arm_group_label>Levodopa/Carbidopa</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 7 to 12

          2. Amblyopia associated with strabismus, anisometropia, or both

               -  Criteria for strabismus: One of the following criteria must be met: Heterotropia
                  at distance and/or near fixation on examination (with or without spectacles);
                  History of strabismus surgery; Documented history of strabismus which is no
                  longer present (which in the judgment of the investigator could have caused
                  amblyopia)

               -  Criteria for anisometropia: One of the following criteria must be met: ≥0.50 D
                  difference between eyes in spherical equivalent; ≥1.50 D difference between eyes
                  in astigmatism in any meridian

          3. Visual acuity, measured in each eye (amblyopic eye without cycloplegia) within 7 days
             prior to enrollment using the E-ETDRS protocol by a study certified visual acuity
             tester as follows:

               -  Visual acuity in the amblyopic eye 18 to 67 letters inclusive (20/50 to 20/400)

               -  Visual acuity in the fellow eye ≥78 letters (20/25 or better)

          4. Current amblyopia treatment (other than spectacles)

               -  12 weeks of at least 2 hours of occlusion per day prescribed for the fellow eye
                  during the immediate pre-enrollment period.

               -  While on current treatment, visual acuity has not improved one line (5 letters)
                  or more since a non-study visit at least 6 weeks ago. Both acuity measurements to
                  define no improvement must have been done using the same testing method.

               -  Treatment with atropine at any time during this pre-enrollment period is not
                  allowed.

               -  Any treatment prior to the current patching episode with stable acuity is
                  acceptable.

          5. Spectacle correction (if applicable) for measurement of enrollment visual acuity must
             meet the following criteria and be based on a cycloplegic refraction that is no more
             than 6 months old:

               1. Requirements for spectacle correction:

                    -  Spherical equivalent must be within 0.50 D of fully correcting the
                       anisometropia.

                    -  Hypermetropia of 3.00D or more must be corrected.

                    -  Hypermetropia must not be under corrected by more than 1.50 D spherical
                       equivalent, and reduction in plus sphere must be symmetric in the two eyes.

                    -  Cylinder power in both eyes must be within 0.50 D of fully correcting the
                       astigmatism.

                    -  Cylinder axis in both eyes is within 6 degrees of the axis in the spectacles
                       when cylinder power is ≥1.00 D.

                    -  Myopia of amblyopic eye greater than 0.50 D by spherical equivalent must be
                       corrected, and the glasses must not under correct the myopia by more than
                       0.25 D or overcorrect it by more than 0.50 D.

               2. Spectacles meeting above criteria must be worn :until visual acuity in amblyopic
                  eye is stable (defined as 2 consecutive visual acuity measurements by the same
                  testing method at least 4 weeks apart with no improvement of one line (5 letters)
                  or more.

          6. Eye examination within 6 months prior to enrollment

          7. Parent available for at least one year of follow-up, has access to phone), and willing
             to be contacted by clinical site and Jaeb Center staff

          8. In the investigator's judgment, the subject is likely to comply with prescribed
             treatment (e.g., no history of poor compliance with patching treatment) and unlikely
             to continue to improve by using 2 hours of patching per day alone.

        Exclusion Criteria:

          1. Myopia more than -6.00 D (spherical equivalent) in either eye.

          2. Current vision therapy or orthoptics

          3. Ocular cause for reduced visual acuity

               -  nystagmus per se does not exclude the subject if the above visual acuity criteria
                  are met

          4. Prior intraocular or refractive surgery

          5. History of narrow-angle glaucoma

          6. Bronchial asthma or severe pulmonary disease

          7. Strabismus surgery planned within 26 weeks

          8. Known allergy to levodopa or carbidopa

          9. History of dystonic reactions

         10. Current use of oral iron supplements including multivitamins containing iron during
             treatment with levodopa-carbidopa

         11. Current use of antihypertensive, anti-depressant medications, phenothiazines,
             butyrophenones, risperidone and isoniazid, non-specific monoamine oxidase inhibitors,
             or medication for the treatment of attention deficit hyperactivity disorder

         12. Known liver disease

         13. History of melanoma

         14. Known psychological problems

         15. Known skin reactions to patch or bandage adhesives

         16. Prior levodopa treatment

         17. Treatment with topical ophthalmic atropine within the past 12 weeks

         18. A physician-prescribed diet high in protein

         19. Females who are pregnant, lactating, or intend to become pregnant within the next 34
             weeks.

               -  A negative urine pregnancy test will be required for all females who have
                  experienced menarche.

               -  Requirements regarding pregnancy testing prior to enrollment may be further
                  defined by each individual Institutional Review Board.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael X Repka, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25676904</url>
    <description>PubMed abstract</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414716/</url>
    <description>PubMed Central HHS Public Access - Full Text</description>
  </link>
  <results_reference>
    <citation>Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, Dean TW, Beck RW, Siatkowski RM, Holmes JM, Beauchamp CL, Golden RP, Miller AM, Verderber LC, Wallace DK. A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology. 2015 May;122(5):874-81. doi: 10.1016/j.ophtha.2015.01.002. Epub 2015 Feb 9.</citation>
    <PMID>25676904</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <results_first_submitted>January 28, 2015</results_first_submitted>
  <results_first_submitted_qc>January 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2015</results_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amblyopia, levodopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified dataset is available on the PEDIG public website at http://pedig.jaeb.org/Studies.aspx?RecID=196</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 2010 and October 2013, 139 participants from 27 sites were randomly assigned to levodopa (n=90) or placebo (n=49).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Levodopa/Carbidopa</title>
          <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2-week Phone Call</title>
              <participants_list>
                <participants group_id="P1" count="87">2 missed, 1 dropped</participants>
                <participants group_id="P2" count="48">1 missed, 0 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>4-week Visit</title>
              <participants_list>
                <participants group_id="P1" count="88">0 missed, 1 dropped</participants>
                <participants group_id="P2" count="47">1 missed, 1 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>7-week Phone Call</title>
              <participants_list>
                <participants group_id="P1" count="85">3 missed, 0 dropped</participants>
                <participants group_id="P2" count="46">2 missed, 0 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>10-week Visit</title>
              <participants_list>
                <participants group_id="P1" count="88">0 missed, 0 dropped</participants>
                <participants group_id="P2" count="48">0 dropped, 0 missed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>13-week Phone Call</title>
              <participants_list>
                <participants group_id="P1" count="82">6 missed, 0 dropped</participants>
                <participants group_id="P2" count="48">0 dropped, 0 missed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>16-week Visit</title>
              <participants_list>
                <participants group_id="P1" count="87">1 dropped</participants>
                <participants group_id="P2" count="46">2 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>18-week Visit (Masked Primary)</title>
              <participants_list>
                <participants group_id="P1" count="87">0 dropped</participants>
                <participants group_id="P2" count="45">1 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>23-week Phone Call</title>
              <participants_list>
                <participants group_id="P1" count="82">4 missed, 1 dropped</participants>
                <participants group_id="P2" count="41">4 missed, 0 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>26-week Visit</title>
              <participants_list>
                <participants group_id="P1" count="86">0 missed, 0 dropped</participants>
                <participants group_id="P2" count="45">0 missed, 0 dropped</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused study treatment after randomized</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levodopa/Carbidopa</title>
          <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="1.8"/>
                    <measurement group_id="B2" value="9.5" spread="1.7"/>
                    <measurement group_id="B3" value="9.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>7 to &lt;9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 to &lt;11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 to &lt;13 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of Amblyopia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Strabismus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anisometropia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined Mechanism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patching Duration at Randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 hours per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3 hours per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity in the Amblyopic Eye at Randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20/200 or worse (&lt;=37 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/100 to &lt;20/200 (38-52 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/80 (53-57 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/63 (58-62 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/50 (63-67 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity in the Amblyopic Eye at Randomization</title>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="9.8"/>
                    <measurement group_id="B2" value="51.7" spread="11.9"/>
                    <measurement group_id="B3" value="52.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity in the Fellow Eye at Randomization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>20/25 (78-82 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/20 (83-87 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/16 (88-92 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/12 (93-97 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Acuity in the Fellow Eye at Randomization</title>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.7" spread="4.1"/>
                    <measurement group_id="B2" value="87.3" spread="3.5"/>
                    <measurement group_id="B3" value="86.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular Visual Acuity Difference at Randomization</title>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="10.9"/>
                    <measurement group_id="B2" value="35.6" spread="13.1"/>
                    <measurement group_id="B3" value="34.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SE Refractive Error in Amblyopic Eye at Randomization</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="2.6"/>
                    <measurement group_id="B2" value="4.5" spread="2.3"/>
                    <measurement group_id="B3" value="4.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SE Refractive Error in Fellow Eye at Randomization</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="2.0"/>
                    <measurement group_id="B2" value="1.6" spread="1.7"/>
                    <measurement group_id="B3" value="1.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anisometropia at Randomization</title>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="2.1"/>
                    <measurement group_id="B2" value="3.1" spread="2.0"/>
                    <measurement group_id="B3" value="2.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline</title>
        <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <population>The ITT principle was followed. For subjects with no visit in the +/- 1 wk window for the 18-wk visit, data from a visit 14-27 wks after randomization were used, if available. Multiple imputation by the Monte Carlo Markov Chain method was used for missing 18-wk VA outcomes based on tx group, baseline VA, &amp; VA scores from completed follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline</title>
          <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <population>The ITT principle was followed. For subjects with no visit in the +/- 1 wk window for the 18-wk visit, data from a visit 14-27 wks after randomization were used, if available. Multiple imputation by the Monte Carlo Markov Chain method was used for missing 18-wk VA outcomes based on tx group, baseline VA, &amp; VA scores from completed follow-up visits.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks</title>
        <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <population>The analysis followed the intent-to-treat principle. For missing primary outcome visits (±1 wk), data from a visit 14-27 wks after randomization were used, if available.Multiple imputation(Monte Carlo Markov Chain method) was used for missing 18-wk VA outcomes based on treatment group, baseline VA, and VA scores from completed follow-up visits</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks</title>
          <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
          <population>The analysis followed the intent-to-treat principle. For missing primary outcome visits (±1 wk), data from a visit 14-27 wks after randomization were used, if available.Multiple imputation(Monte Carlo Markov Chain method) was used for missing 18-wk VA outcomes based on treatment group, baseline VA, and VA scores from completed follow-up visits</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A sample size of 129 participants provided 80% power with 1-sided type I error rate of 5% to reject the hypothesis of no difference between groups if the proportion improved was 30% in the levodopa group compared with 10% in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Fisher Exact</method>
            <method_desc>It was not possible to adjust for baseline VA in these secondary analyses due to the small number of subjects meeting secondary outcome criteria.</method_desc>
            <param_type>Percent Difference</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
            <estimate_desc>Treatment group difference calculated as Levodopa - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity at 18 Weeks</title>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity at 18 Weeks</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 (78-82 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 (73-77 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/40 (68-72 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/50 (63-67 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/63 (58-62 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/80 (53-57 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/100 (48-52 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/125 (43-47 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/160 or worse (&lt;=42 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Amblyopic Eye Visual Acuity at 18 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Amblyopic Eye Visual Acuity at 18 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="8.9"/>
                    <measurement group_id="O2" value="54.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 4 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 4 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not improve 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17</ci_lower_limit>
            <ci_upper_limit>18</ci_upper_limit>
            <estimate_desc>Levodopa - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 10 Weeks</title>
        <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 10 Weeks</title>
          <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Difference</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 16 Weeks</title>
        <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 16 Weeks</title>
          <description>Treatment group comparisons of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
            <estimate_desc>Levodopa - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 26 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 26 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects who have improved from baseline by 10 or more letters.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not improved 10 or more letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopia Resolutionat 4 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia Resolutionat 4 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 or worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopia Resolution at 10 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia Resolution at 10 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 or worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopia Resolution at 16 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia Resolution at 16 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 or worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopia Resolution at 18 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia Resolution at 18 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 or worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amblyopia Resolution at 26 Weeks</title>
        <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia Resolution at 26 Weeks</title>
          <description>Treatment group comparisons adjusted for baseline acuity scores using logistic regression of the proportion of subjects with 20/25 or better visual acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/25 or better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 or worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 4 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 4 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 4 Weeks</title>
        <description>A treatment group comparison of the mean amblyopic eye visual acuity at 4 weeks after enrollment, adjusted for baseline acuity.</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 4 Weeks</title>
          <description>A treatment group comparison of the mean amblyopic eye visual acuity at 4 weeks after enrollment, adjusted for baseline acuity.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="4.1"/>
                    <measurement group_id="O2" value="2.5" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Mean difference calculated as Levodopa - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 10 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 10 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 10 Weeks</title>
        <description>A treatment group comparison of the mean amblyopic eye visual acuity at 10 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 10 Weeks</title>
          <description>A treatment group comparison of the mean amblyopic eye visual acuity at 10 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.9"/>
                    <measurement group_id="O2" value="3.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 16 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 16 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 16 Weeks</title>
        <description>A treatment group comparison of the mean amblyopic eye visual acuity at 16 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 16 Weeks</title>
          <description>A treatment group comparison of the mean amblyopic eye visual acuity at 16 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="6.3"/>
                    <measurement group_id="O2" value="4.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 26 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Amblyopic Eye Visual Acuity Change From Baseline at 26 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 15 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 26 Weeks</title>
        <description>A treatment group comparison of the mean amblyopic eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Amblyopic Eye Visual Acuity From Baseline at 26 Weeks</title>
          <description>A treatment group comparison of the mean amblyopic eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity. Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="5.7"/>
                    <measurement group_id="O2" value="4.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Fellow Eye Visual Acuity at 18 Weeks</title>
        <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 18 weeks after enrollment, adjusted for baseline acuity.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Fellow Eye Visual Acuity at 18 Weeks</title>
          <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 18 weeks after enrollment, adjusted for baseline acuity.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/12 (93-97 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/16 (88-92 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/20 (83-87 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/25 (78-82 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 (73-77 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fellow Eye Visual Acuity at 18 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fellow Eye Visual Acuity at 18 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="4.4"/>
                    <measurement group_id="O2" value="88.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=15 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Amblyopic Eye Visual Acuity Change From Baseline</title>
        <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <population>The ITT principle was followed. For subjects with no visit in the +/- 1 wk window for the 18-wk visit, data from a visit 14-27 wks after randomization were used, if available. Multiple imputation by the Monte Carlo Markov Chain method was used for missing 18-wk VA outcomes based on tx group, baseline VA, &amp; VA scores from completed follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Amblyopic Eye Visual Acuity Change From Baseline</title>
          <description>The primary outcome is the amblyopic eye visual acuity letter score measured at the 18-week primary outcome visit following a rapid taper of study medicine beginning at week 16. The primary analytic approach will be a treatment group comparison of the mean amblyopic eye visual acuity adjusted for baseline acuity.
Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <population>The ITT principle was followed. For subjects with no visit in the +/- 1 wk window for the 18-wk visit, data from a visit 14-27 wks after randomization were used, if available. Multiple imputation by the Monte Carlo Markov Chain method was used for missing 18-wk VA outcomes based on tx group, baseline VA, &amp; VA scores from completed follow-up visits.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.3"/>
                    <measurement group_id="O2" value="3.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>With 129 participants, assuming a 1-sided type I error rate of 4.85%, there was 96% power to detect a difference in mean visual acuity between treatment groups at 18 weeks adjusted for baseline and for 1 interim analysis for futility if the true difference was 5 letters with SD of 7 letters and 82% power if the true difference was 3.75 letters</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>The alpha level was set to 0.0485 for the primary analysis to adjust for alpha spending of 0.015 for one interim analysis for efficacy conducted when outcome data were available for 50% of participants.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Mean difference calculated as Levodopa - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fellow Eye Visual Acuity Change From Baseline at 18 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.0"/>
                    <measurement group_id="O2" value="0.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at Enrollment</title>
        <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>At enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at Enrollment</title>
          <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.37"/>
                    <measurement group_id="O2" value="1.73" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at 4 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at 4 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.37"/>
                    <measurement group_id="O2" value="1.51" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at 10 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at 10 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.31"/>
                    <measurement group_id="O2" value="1.42" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at 16 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at 16 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.27"/>
                    <measurement group_id="O2" value="1.38" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at 18 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at 18 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.22"/>
                    <measurement group_id="O2" value="1.28" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Child Symptom Survey Score at 26 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Child Symptom Survey Score at 26 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.26"/>
                    <measurement group_id="O2" value="1.33" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at Enrollment</title>
        <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>At enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at Enrollment</title>
          <description>A treatment group comparison of symptom survey scores at enrollment. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.34"/>
                    <measurement group_id="O2" value="1.44" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at 4 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>4 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at 4 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 4 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.27"/>
                    <measurement group_id="O2" value="1.26" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at 10 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at 10 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 10 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.22"/>
                    <measurement group_id="O2" value="1.30" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at 16 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>16 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at 16 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 16 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.27"/>
                    <measurement group_id="O2" value="1.25" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at 18 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>18 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at 18 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the primary outcome (18 week) visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.21"/>
                    <measurement group_id="O2" value="1.17" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Parent Symptom Survey Score at 26 Weeks</title>
        <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Parent Symptom Survey Score at 26 Weeks</title>
          <description>A treatment group comparison of symptom survey scores at the 26 week visit. The average of the overall item responses will be calculated and compared by treatment group with a t-test for difference in means. A higher number reflects a more negative response (5=always, 4=often, 3=sometimes, 2=rarely, 1=never).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.24"/>
                    <measurement group_id="O2" value="1.22" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systemic Adverse Events</title>
        <time_frame>Enrollment through 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systemic Adverse Events</title>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.39"/>
                    <measurement group_id="O2" value="1.55" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Fellow Eye Visual Acuity at 26 Weeks</title>
        <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Fellow Eye Visual Acuity at 26 Weeks</title>
          <description>Similar to the analysis for the amblyopic eye, the fellow eye visual acuity will be evaluated to determine if study treatment had an adverse effect on the occluded eye. The analysis will be a treatment group comparison of the mean fellow eye visual acuity at 26 weeks after enrollment, adjusted for baseline acuity.</description>
          <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20/12 (93-97 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/16 (88-92 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/20 (83-87 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/25 (78-82 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20/32 (73-77 letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fellow Eye Visual Acuity at 26 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fellow Eye Visual Acuity at 26 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" spread="4.5"/>
                    <measurement group_id="O2" value="88.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <population>All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 participants in the levodopa group and 24 participants in the placebo group continued study medication at the 18-week visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=15 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>within 4 letters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-9 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-14 letters better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</title>
        <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
        <time_frame>26 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levodopa/Carbidopa</title>
            <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fellow Eye Visual Acuity Change From Baseline at 26 Weeks</title>
          <description>Visual acuity was measured in each eye (right eye first) by a study-certified VA tester using the Electronic Early Treatment of Diabetic Retinopathy Study (E-ETDRS©) visual acuity protocol. Five letters is equivalent to one logMAR line.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.6"/>
                    <measurement group_id="O2" value="0.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to last follow-up visit (26 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levodopa/Carbidopa</title>
          <description>Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
Levodopa/Carbidopa: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Patching: Two hours of daily patching</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral placebo tid
Placebo: Oral placebo tid
Patching: Two hours of daily patching</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Kraker, M.S.P.H., Director of PEDIG Coordinating Center</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>813-975-8690</phone>
      <email>rkraker@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

